Application of butyric acid compound in preparing drug or functional food for treating ischemic stroke

Abstract

The invention discloses application of a butyric acid compound in preparing a drug or functional food for treating ischemic stroke. The drug or the functional food comprises the butyric acid compound,wherein the concentration of the butyric acid compound is 20-100 micromoles per liter, and the effective dose of the butyric acid compound as the drug is 5-50 mg / kg / d. After oral administration, thebutyric acid compound can effectively reduce the area of cerebral infarction, significantly restore the neurological damages caused by the ischemic stroke, ameliorate dyslipidemia caused by the ischemic stroke, and effectively reduce the blood viscosity, the fibrinogen content and the platelets aggregation rate, thereby ameliorating the complications induced by the ischemic stroke in many aspectsand effectively treating the ischemic stroke.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to the application of a butyric acid compound in the preparation of medicine or functional food for treating ischemic stroke. Background technique [0002] Ischemic stroke (Cerebral ischemic stroke) is a central nervous system disease that seriously threatens human life and is characterized by high morbidity, disability and mortality. There are currently 70 million stroke patients in my country, including 2 million new patients each year, 20 million high-risk non-disabled patients, and a disability fatality rate of 30-40%. On average, one Chinese person has a stroke every 12 seconds. In 21 seconds, a Chinese dies of a stroke. Among stroke patients, ischemic stroke accounts for 69.6%, and ischemic stroke has become the disease with the highest mortality rate among Chinese residents. When the brain ischemia, acute hypoxia can lead to lack of energy metabolism, resulting in ischemic dam...

AI Technical Summary

Problems solved by technology

In my country’s guidelines for the prevention and treatment of cardiovascular and cerebrovascular diseases, intravenous injection of 0.9 mg / kg of recombinant tissue plasminogen activator (r-tPA) is recommended as the standard treatment for acute ischemic stroke, r -tPA is the only drug approved by the US FDA for intravenous thrombolysis, but its treatment time window is only 4.5 hours. Therefore, the vast majority of patients in my country cannot be effectively treated within the time window. Moreover, the application of r-tPA Reperfusion after thrombolysis can induce cascade reaction of free radicals and inflammatory reactions, etc., causing secondary injury of ischemia-reperfusion and aggravating the damage to brain tissue. In addition, the application of r-tPA thrombolysis can also activate the systemic fibrinolytic system and further Causes such as secondary intracranial hemorrhage and other complications, the above shortcomings seriously limit the clinical application of r-tPA

In view of the complex pathogenesis of ischemic stroke, including calcium overload, inflammation, apoptosis, and nerve regeneration and repair disorders, the effect of r-tPA thrombolytic therapy alone is not ideal

Images